DNA methylation in psychosis: Insights into etiology and treatment

Epigenomics

Volumn 7, Issue 1, 2015, Pages 67-74

  Castellani, Christina A ^a   Melka, Melkaye G ^a   Diehl, Eric J ^a   Laufer, Benjamin I ^a   O'Reilly, Richard L ^b   Singh, Shiva M ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

antipsychotics; DNA methylation; environment; epigenomics; exposure; mental disorders; monozygotic twins; olanzapine; psychosis

Indexed keywords

DNA; NEUROLEPTIC AGENT;

DNA METHYLATION; DOPAMINERGIC ACTIVITY; HUMAN; MENTAL DISEASE; MONOZYGOTIC TWINS; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TWINS; ANIMAL; DRUG EFFECTS; GENETICS; PSYCHOTIC DISORDERS; RAT;

RATTUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DNA METHYLATION; HUMANS; PSYCHOTIC DISORDERS; RATS;

EID: 84923223082     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.66     Document Type: Review

References (73)

1. Bell JT, Saffery R. The value of twins in epigenetic epidemiology. Int. J. Epidemiol. 41(1), 140-150 (2012).
2. McCarthy MI, Hirschhorn JN. Genome-wide association studies: potential next steps on a genetic journey. Hum. Mol. Genet. 17(R2), r156-r165 (2008).
3. Mill J, Tang T, Kaminsky Z et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 82(3), 696-711 (2008).
4. Razin A, Riggs AD. DNA methylation and gene function. Science 210(4470), 604-610 (1980).
5. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 366(6453), 362-365 (1993).
6. Shukla S, Kavak E, Gregory M et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 479(7371), 74-79 (2011).
7. Xu GL, Bestor TH, Bourchis D et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402(6758), 187-191 (1999).
8. Zhao J, Wang F, Xu Z, Fan Y. The epigenetic effect on pre-mRNA alternative splicing. Yi Chuan 36(3), 248-255 (2014).
9. Alvarado S, Fernald RD, Storey KB, Szyf M. The dynamic nature of DNA methylation: a role in response to social and seasonal variation. Integr. Comp. Biol. 54(1), 68-76 (2014).
10. Singh SM, Murphy B, OReilly RL. Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: from cancer to schizophrenia. Clin. Genet. 64(6), 451-460 (2003).
11. Kapur S, Barsoum SC, Seeman P. Dopamine D(2) receptor blockade by haloperidol: (3)H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology 23(5), 595-598 (2000).
12. Farah A. Atypicality of atypical antipsychotics. Prim. Care Companion: J. Clin. Psychiatry 7(6), 268-274 (2005).
13. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47(1), 27-38 (2002).
14. Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20(5), 389-409 (2006).
15. Clark SL, Adkins DE, van den Oord EJ. Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr. Res. 132(2-3), 114-120 (2011).
16. Reynolds GP, McGowan OO, Dalton CF. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br. J. Clin. Pharmacol. 77(4), 654-672 (2014).
17. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv. Rev. Psychiatry 15(5), 245-258 (2007).
18. Lencz T, Malhotra AK. Pharmacogenetics of antipsychoticinduced side effects. Dialogues Clin. Neurosci. 11(4), 405-415 (2009).
19. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychoticinduced weight gain: review and clinical implications. Mol. Psychiatry 17(3), 242-266 (2012).
20. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7(6), 863-887 (2006).
21. Dong E, Grayson DR, Guidotti A, Costa E. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics 1(1), 201-211 (2009).
22. Kelkar A, Deobagkar D. A novel method to assess the full genome methylation profile using monoclonal antibody combined with the high throughput based microarray approach. Epigenetics 4(6), 415-420 (2009).
23. Pishva E, Kenis G, van den Hove D et al. The epigenome and postnatal environmental influences in psychotic disorders. Soc. Psychiatry Psychiatr. Epidemiol. 49(3), 337-348 (2014).
24. McGuffin P, Asherson P, Owen M, Farmer A. The strength of the genetic effect: is there room for an environmental influence in the aetiology of schizophrenia? Br. J. Psychiatry 164(5), 593-599 (1994).
25. Ripke S et al. Psychiatric genomics consortium: biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-437 (2014).
26. Singh SM, Murphy B, OReilly R. Epigenetic contributors to the discordance of monozygotic twins. Clin. Genet. 62(2), 97-103 (2002).
27. Weinberger DR, Mattay V, Callicott J et al. fMRI applications in schizophrenia research. Neuroimage 4(3 Pt 3), S118-S126 (1996).
28. Singh SM, McDonald P, Murphy B, OReilly R. Incidental neurodevelopmental episodes in the etiology of schizophrenia: an expanded model involving epigenetics and development. Clin. Genet. 65(6), 435-440 (2004).
29. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 17(12), 1228-1238 (2012).
30. Wockner LF, Noble EP, Lawford BR et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl. Psychiatry 4, e339 (2014).
31. Kinoshita M, Numata S, Tajima A et al. DNA methylation signatures of peripheral leukocytes in schizophrenia. Neuromolecular Med. 15(1), 95-101 (2013).
32. Murphy BC, Chiu T, Harrison M, Uddin RK, Singh SM. Examination of ethanol responsive liver and brain specific gene expression, in the mouse strains with variable ethanol preferences, using cDNA expression arrays. Biochem. Genet. 40(11-12), 395-410 (2002).
33. Shimabukuro M, Jinno Y, Fuke C, Okazaki Y. Haloperidol treatment induces tissue-and sex-specific changes in DNA methylation: a control study using rats. Behav. Brain Funct. 2, 37 (2006).
34. Bonsch D, Wunschel M, Lenz B, Janssen G, Weisbrod M, Sauer H. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Res. 198(3), 533-537 (2012).
35. Dempster EL, Pidsley R, Schalkwyk LC et al. Diseaseassociated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 20(24), 4786-4796 (2011).
36. Melka MG, Laufer BI, McDonald P et al. The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clin. Epigenetics 6(1), 7083-7086 (2014).
37. Auta J, Smith RC, Dong E et al. DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. Schizophr. Res. 150(1), 312-318 (2013).
38. Ollikainen M, Smith KR, Joo EJ et al. DNA methylation analysis of multiple tissues from newborn twins reveals both genetic and intrauterine components to variation in the human neonatal epigenome. Hum. Mol. Genet. 19(21), 4176-4188 (2010).
39. Singh SM, OReilly R. (Epi)genomics and neurodevelopment in schizophrenia: monozygotic twins discordant for schizophrenia augment the search for disease-related (epi) genomic alterations. Genome 52(1), 8-19 (2009).
40. Maiti S, Kumar KH, Castellani CA, OReilly R, Singh SM. Ontogenetic de novo copy number variations (CNVs) as a source of genetic individuality: studies on two families with MZD twins for schizophrenia. PLoS One 6(3), e17125 (2011).
41. Castellani CA, Awamleh Z, Melka MG, OReilly RL, Singh SM. Copy number variation distribution in six monozygotic twin pairs discordant for schizophrenia. Twin Res. Hum. Genet. 17(2), 108-120 (2014).
42. Kim K, Ban HJ, Seo J et al. Genetic factors underlying discordance in chromatin accessibility between monozygotic twins. Genome Biol. 15(5), R72 (2014).
43. Wong CM, Anderton DL, Smith-Schneider S, Wing MA, Greven MC, Arcaro KF. Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women. Epigenetics 5(7), 645-655 (2010).
44. Byrne EM, Carrillo-Roa T, Henders AK et al. Monozygotic twins affected with major depressive disorder have greater variance in methylation than their unaffected co-twin. Transl. Psychiatry 3, e269 (2013).
45. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276(39), 36734-36741 (2001).
46. Sharma RP, Rosen C, Kartan S et al. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophr. Res. 88(1-3), 227-231 (2006).
47. Kurita M, Holloway T, Garcia-Bea A et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15(9), 1245-1254 (2012).
48. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E. In psychosis, cortical interneurons overexpress DNAmethyltransferase 1. Proc. Natl Acad. Sci. USA 102(6), 2152-2157 (2005).
49. Melka MG, Castellani CA, Laufer BI, Rajakumar RN, OReilly R, Singh SM. Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis. J. Mol. Psych. 1(19), 1-7 (2013).
50. Abdolmaleky HM, Nohesara S, Ghadirivasfi M et al. DNA hypermethylation of serotonin transporter gene promoter in drug naive patients with schizophrenia. Schizophr. Res. 152(2-3), 373-380 (2014).
51. Allen NC, Bagade S, McQueen MB et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40(7), 827-834 (2008).
52. Bignante EA, Rodriguez Manzanares PA, Mlewski EC et al. Involvement of septal Cdk5 in the emergence of excessive anxiety induced by stress. Eur. Neuropsychopharmacol. 18(8), 578-588 (2008).
53. Zhu WL, Shi HS, Wang SJ et al. Increased Cdk5/p35 activity in the dentate gyrus mediates depressive-like behaviour in rats. Int. J. Neuropsychopharmacol. 15(6), 795-809 (2012).
54. Yu M, Li W, Luo S et al. Folic acid stimulation of neural stem cell proliferation is associated with altered methylation profile of PI3K/Akt/CREB. J. Nutr. Biochem. 25(4), 496-502 (2014).
55. Murata Y, Nishioka M, Bundo M, Sunaga F, Kasai K, Iwamoto K. Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin. Neurosci. Lett. 563, 123-128 (2014).
56. Tang H, Dalton CF, Srisawat U, Zhang ZJ, Reynolds GP. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. Int. J. Neuropsychopharmacol. 17(4), 645-649 (2014).
57. Santoro ML, Ota VK, Stilhano RS et al. Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR). Schizophr. Res. 157, 163-168 (2014).
58. Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A. Analysis of association between dopamine receptor genes methylation and their expression profile with the risk of schizophrenia. Psychiatr. Genet. 23(5), 183-187 (2013).
59. Yeh TK, Hu CY, Yeh TC et al. Association of polymorphisms in BDNF, MTHFR, and genes involved in the dopaminergic pathway with memory in a healthy Chinese population. Brain Cogn. 80(2), 282-289 (2012).
60. Razin A, Kantor B. DNA methylation in epigenetic control of gene expression. Prog. Mol. Subcell. Biol. 38, 151-167 (2005).
61. Donohoe G, Walters J, Morris DW et al. Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Arch. Gen. Psychiatry 66(10), 1045-1054 (2009).
62. Green EK, Grozeva D, Jones I et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry 15(10), 1016-1022 (2010).
63. Meyer-Lindenberg A, Straub RE, Lipska BK et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J. Clin. Invest. 117(3), 672-682 (2007).
64. Pal P, Mihanovic M, Molnar S et al. Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic pathway with schizophrenia in Croatian population. Croat. Med. J. 50(4), 361-369 (2009).
65. Abdolmaleky HM, Cheng KH, Faraone SV et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 15(21), 3132-3145 (2006).
66. Weth O, Renkawitz R. CTCF function is modulated by neighboring DNA binding factors. Biochem. Cell Biol. 89(5), 459-468 (2011).
67. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci. 30(2), 55-60 (2009).
68. Redies C, Hertel N, Hubner CA. Cadherins and neuropsychiatric disorders. Brain Res. 1470, 130-144 (2012).
69. Hirano S, Takeichi M. Cadherins in brain morphogenesis and wiring. Physiol. Rev. 92(2), 597-634 (2012).
70. Grayson DR, Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 38(1), 138-166 (2013).
71. Guidotti A, Auta J, Chen Y et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 60(7-8), 1007-1016 (2011).
72. Grayson DR, Jia X, Chen Y et al. Reelin promoter hypermethylation in schizophrenia. Proc. Natl Acad. Sci. USA 102(26), 9341-9346 (2005).
73. Aberg KA, Xie LY, McClay JL et al. Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions. Epigenomics 5(4), 367-377 (2013).